布地奈德雾化和口服泼尼松龙治疗COPD急性加重期的疗效比较
慢性阻塞性肺疾病,,慢性阻塞性肺疾病；,急性加重期；,布地奈德；,泼尼松龙,1资料与方法,2结果,3讨论,参考文献：
摘要：目的：观察比较布地奈德雾化和口服泼尼松龙治疗慢性阻塞性肺疾病(COPD)急性加重期的临床疗效。方法：180例COPD急性加重期住院患者随机分为3组，分别给予布地奈德雾化和口服泼尼松龙与安慰剂进行对照治疗，观察3组患者肺功能、动脉血气及副反应情况。结果：布地奈德雾化和口服泼尼松龙组第一秒末最大呼气流量(FEV1)和动脉血气的改善程度明显优于安慰剂组，而布地奈德雾化组和口服泼尼松龙组间差异无统计学意义。布地奈德雾化组的副作用明显少于口服泼尼松龙组，与安慰剂组相仿。结论：布地奈德雾化是治疗COPD急性加重期的有效方法。关键词：慢性阻塞性肺疾病； 急性加重期； 布地奈德； 泼尼松龙
Comparison of the efficacy of nebulised budesonide with oral prednisolone in
treatment of acute exacerbations of chronic obstructive pulmonary diseaseDAI
Yuemei, JIAO Kegang
(Department of Respiration, First Affiliation Hospital, Xinjiang Medical University, Urumqi 830054, China)
Abstract: Objective: To evaluate the effect of nebulized Budesonide and oral prednisolone in treatment of acute exacerbations of chronic obstructive pulmonary disease(COPD). Method: One hundred and eighty patients with acute exacerbation of COPD were randomized to divide into 3 groups, nebulised budesonide groups, oral prednisolone groups and placebocontrolled groups. Pulmonary function, arterial blood gases analysis and the adverse effects were measured. Result: Compared with the placebo groups, There were significant differences in the improvement of FEV1 (Forced expiratory volume in one second) of nebulized budesonide and oral prednisolone groups than placebo group, but there were no significant differences between of nebulized budesonide groups and oral prednisolone groups. The adverse effects in nebulised budesonide group were obviously less than those in oral prednisolone groups, but were similar with the placebo groups. Conclusion: Nebulized budesonide was an effective method in treatment of acute exacerbations of chronic obstructive pulmonary disease. ......
您现在查看是摘要页，全文长 8313 字符。